In this review:
- DEDiCa: breast cancer recurrence with a Mediterranean diet, brisk walking and vitamin D
- IRIS-A: adjuvant capecitabine trastuzumab in stage IA HER2+ breast cancer
- Yoga for cancer survivors (YOCAS©®)
- lidERA: results in pre/post menopausal patients
- HELEN-Trio 011: neoadjuvant camrelizumab + docetaxel carboplatin in TNBC
- OPTIMA: test-directed therapy in ER+/HER2– early breast cancer
- persevERA: giredestrant-palbociclib vs. letrozole-palbociclib in ER+/ HER2– breast cancer
- Neo-Healer: anbenitamab + nab-docetaxel ± carboplatin in HER2+ breast cancer
- SENOMAC: omission of cALND after positive sentinel lymph node biopsy
- KEYNOTE-522: neoadjuvant pembrolizumab + chemotherapy + adjuvant pembrolizumab in early-stage TNBC
Please login below to download this issue (PDF)